ofatumumab (GSK1841157) infusion

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, GlaxoSmithKline

Conditions

Leukaemia, Lymphocytic, Chronic

Phase 2

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

CompletedNCT01563055

GlaxoSmithKlineLeukaemia, Lymphocytic, Chronic

Start: 2012-04-30End: 2014-11-30Updated: 2015-08-10

Phase 3

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

TerminatedNCT00748189

Novartis PharmaceuticalsLeukaemia, Lymphocytic, Chronic

Start: 2008-12-22End: 2018-05-17Updated: 2019-06-25

Related Papers

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

Haematologica2020-01-0938 citations

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

Journal of Clinical Oncology2019-05-202 citations

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.

2015-04-14238 citations